Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer

This publication has 14 references indexed in Scilit:

• Estimates of the cancer incidence and mortality in Europe in 2006
  Annals of Oncology, 2007
• Interview with Professor Ulf Tunn: LHRHa: What’s new?
  European Urology, 2007
• Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: Results of a randomized open-label trial
  Urology, 2004
• Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: part II. In vivo performance
  European Journal of Pharmaceutics and Biopharmaceutics, 2004
• An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists
  Urology, 2003
• THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ABARELIX DEPOT VERSUS LUTEINIZING HORMONE RELEASING HORMONE AGONISTS LEUPROLIDE OR GOSERELIN: INITIAL RESULTS OF ENDOCRINOLOGICAL AND BIOCHEMICAL EFFICACIES IN PATIENTS WITH PROSTATE CANCER
  Journal of Urology, 2001
• GnRH Antagonists: A New Generation of Long Acting Analogues Incorporatingp-Ureido-phenylalanines at Positions 5 and 6
  Journal of Medicinal Chemistry, 2000
• DISEASE FLARE INDUCED BY D-Trp6-LHRH ANALOGUE IN PATIENTS WITH METASTATIC PROSTATIC CANCER
  The Lancet, 1984
• Pituitary desensitization and the regulation of pituitary gonadotropin-releasing hormone (GnRH) receptors following chronic administration of a superactive GnRH analog and testosterone
  Life Sciences, 1982
• A Peptide Inhibitor of Luteinizing Hormone-Releasing Hormone (LH-RH)
  Journal of Clinical Endocrinology & Metabolism, 1973